查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813955

類澱粉沉積症治療市場規模、佔有率和趨勢分析報告：按治療、最終用途、地區和細分市場預測，2025-2033 年

Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care), By End Use ( Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

類澱粉沉積症治療市場摘要

預計 2024 年全球類澱粉沉積症治療市值為 58 億美元，到 2033 年將達到 111.3 億美元，2025 年至 2033 年的複合年成長率為 7.5%。

該行業的成長得益於人們對疾病認知的提高、診斷方法的進步以及由於診斷準確而得到早期診斷的患者數量的增加。

先進成像、質譜分析和基因檢測等技術創新使醫療保健提供者能夠更好地區類澱粉沉積症變性亞型，從而支持更精準有效的治療方法。專科醫療中心的建立和訓練有素的醫療專業人員的配備，進一步改善了綜合治療的可及性。此外，與老齡化相關的轉甲狀腺素類澱粉沉積症變性發病率不斷上升，尤其是在老年族群中，這推動了對長期治療方案的需求。類澱粉沉積症是一種可以透過及時治療有效控制的疾病，這項認知正在改變全球患者照護實踐。

推動類澱粉沉積症治療市場的主要因素之一是針對轉甲狀腺素類澱粉沉積症基因靜默療法的監管收緊。例如，2025 年 3 月，美國FDA核准Amvuttra (vutrisiran) 作為首個針對轉甲狀腺素蛋白澱粉樣變性心肌病(ATTR-CM) 的基因靜默療法。此項核准基於 III 期 HELIOS-B 試驗的結果，該結果顯示全因死亡率和心血管事件減少了 28%。患者的功能能力和生活品質也得到了顯著改善。這項進展提供了一種新的治療途徑，每年只需注射四次即可直接減少 TTR 蛋白的產生。預計此項核准將促進早期診斷，擴大基於 RNA 的治療方法的採用，並加劇 ATTR-CM 市場的競爭。

針對轉甲狀腺素類澱粉沉積症的高效小分子穩定劑已獲得監管部門核准，是推動類澱粉沉積症治療市場發展的重大進展。例如，2024年12月，美國FDA核准了BridgeBio Pharma開發的近乎完全的轉甲狀腺素蛋白(TTR)穩定劑Attruvy (Acoramidis)，用於治療心肌病(ATTR-CM)。在關鍵的ATTRibute-CM試驗中，Acoramidis顯示出超過90%的TTR穩定性，並顯著降低了心血管死亡和住院率。此次核准拓寬了RNAi治療方法以外的治療選擇，引入了一種方便的口服替代方案，可滿足更廣泛患者群體的需求。預計這將加劇市場競爭並加速ATTR-CM治療的技術創新。憑藉更高的療效、耐受性和易用性，Acoramidis有望重塑新診斷和長期ATTR-CM患者的治療模式。

癌症患者數量快速成長，預計到2050年，美國將成長47.5%，加拿大將成長60.7%，這導致慢性疾病和多重併發症的盛行率上升。這一趨勢凸顯了醫療保健系統日益加重的負擔，進而加速了先進診斷和治療解決方案的需求。鑑於癌症和類澱粉沉積症在臨床上面臨共同挑戰，包括器官功能障礙、蛋白質錯誤折疊和全身性炎症，癌症發病率的上升間接提高了人們對類澱粉沉積症等相關疾病的認知和識別。這種關聯可能會推動患者篩檢的增加、醫療保健投資的擴大以及治療基礎設施的增強。

因此，隨著癌症發病率的上升推動臨床認知和治療創新，預計該行業將從這些動態中受益。精準醫療需求的不斷成長，可能促使人們更加關注單株抗體、標靶治療以及更有效控制疾病進展的支持性護理解決方案。此外，製藥公司和醫療保健提供者可能會增加研究資金和合作，利用腫瘤學的進步來加速類澱粉沉積症的研究和開發。這些協同效應預計將在未來幾十年推動類澱粉沉積症市場的顯著成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章類澱粉沉積症治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章類澱粉沉積症治療市場：治療業務分析

  • 2024年和2033年的治療市場佔有率
  • 治療細分儀表板
  • 2021-2033 年治療學市場規模、預測與趨勢分析
  • 化療
  • 免疫抑制劑
  • 移植
  • 支持性護理
  • 外科手術
  • 其他

第5章類澱粉沉積症治療市場：最終用途業務分析

  • 2024年和2033年的最終用途市場佔有率
  • 最終用途細分儀表板
  • 市場規模、預測與趨勢分析（依最終用途，2021-2033 年）
  • 醫院和診所
  • 門診手術中心
  • 居家照護環境
  • 其他

第6章類澱粉沉積症治療市場：區域估計與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場儀表板
  • 2021-2033年市場規模與預測趨勢分析
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • GSK plc
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Merck KGaA
    • Sanofi
    • Alnylam Pharmaceuticals, Inc.
Product Code: GVR-2-68038-443-7

Amyloidosis Treatment Market Summary

The global amyloidosis treatment market size was estimated at USD 5.80 billion in 2024 and is projected to reach USD 11.13 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The industry is experiencing growth due to rising awareness of the disease, advancements in diagnostic methods, and an increasing number of patients being identified at earlier stages with accurate diagnoses.

Innovations such as advanced imaging, mass spectrometry, and genetic testing are allowing healthcare providers to better distinguish between amyloidosis subtypes, supporting more precise and effective treatment approaches. The establishment of specialized care centers and the availability of trained medical experts are further enhancing access to comprehensive care. Additionally, the growing incidence of age-related transthyretin amyloidosis, particularly among older populations, is driving demand for long-term therapeutic solutions. These factors are prompting pharmaceutical companies to expand their research pipelines, while the recognition of amyloidosis as a condition that can be effectively managed with timely treatment is transforming global patient care practices.

One of the key drivers fueling the amyloidosis treatment market is the regulatory advancement of gene-silencing therapies for transthyretin amyloidosis. For instance, in March 2025, the U.S. FDA approved Amvuttra (vutrisiran) as the first gene-silencing therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). The approval was backed by Phase III HELIOS-B trial results showing a 28% reduction in all-cause mortality and cardiovascular events. Patients also experienced notable improvements in functional capacity and quality of life. This advancement offers a new treatment pathway directly reducing TTR protein production with only four annual injections. The approval is expected to boost early diagnosis, expand RNA-based therapy adoption, and intensify competition in the ATTR-CM market.

The regulatory approval of highly effective small-molecule stabilizers targeting transthyretin amyloidosis is a major development boosting the amyloidosis treatment market. For instance , in December 2024, the U.S. FDA approved Attruby (acoramidis), a near-complete transthyretin (TTR) stabilizer developed by BridgeBio Pharma, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) (BridgeBio). Acoramidis demonstrated over 90% stabilization of TTR and significantly reduced cardiovascular death and hospitalizations in the pivotal ATTRibute-CM trial. The approval introduces a convenient oral alternative that expands treatment options beyond RNAi-based therapies and meets the needs of a broader patient base. It is expected to intensify market competition and accelerate innovation in ATTR-CM therapeutics. With improved efficacy, tolerability, and ease of administration, acoramidis is positioned to reshape treatment paradigms for newly diagnosed and long-term ATTR-CM patients.

The projected surge in cancer cases, with the United States expected to see a 47.5% increase and Canada a 60.7% increase by 2050, the rising prevalence of chronic and complex diseases. This trend emphasizes the growing strain on healthcare systems, which in turn accelerates demand for advanced diagnostics and treatment solutions. Given that cancer and amyloidosis share overlapping clinical challenges such as organ dysfunction, protein misfolding, and systemic inflammation, the increase in cancer incidence indirectly raises awareness and identification of related conditions like amyloidosis. This linkage is likely to enhance patient screening, expand healthcare investments, and strengthen treatment infrastructure.

Consequently, the industry is expected to benefit from these dynamics as rising cancer prevalence fuels both clinical awareness and therapeutic innovation. With heightened demand for precision therapies, there will be an increased focus on monoclonal antibodies, targeted treatments, and supportive care solutions that address disease progression more effectively. Moreover, pharmaceutical companies and healthcare providers are likely to increase research funding and collaborations, leveraging advancements in oncology to accelerate drug development for amyloidosis. This synergy will position the amyloidosis market for significant growth in the coming decades.

Global Amyloidosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amyloidosis treatment market report based on treatment, end-use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Immunosuppressive Drugs
  • Transplantation
  • Supportive Care
  • Surgery
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End-use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Amyloidosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Amyloidosis Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.5. Immunosuppressive Drugs
    • 4.5.1. Immunosuppressive Drugs Market, 2021 - 2033 (USD Million)
  • 4.6. Transplantation
    • 4.6.1. Transplantation Market, 2021 - 2033 (USD Million)
  • 4.7. Supportive Care
    • 4.7.1. Supportive Care Market, 2021 - 2033 (USD Million)
  • 4.8. Surgery
    • 4.8.1. Surgery Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Amyloidosis Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals & Clinics
    • 5.4.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 5.5. Ambulatory Surgical Centers
    • 5.5.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Home Care Settings
    • 5.6.1. Home Care Settings Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Amyloidosis Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 6.4. North America
    • 6.4.1. North America Amyloidosis Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Johnson & Johnson Services, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. GSK plc
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Takeda Pharmaceutical Company Limited
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Amgen Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bristol-Myers Squibb Company
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. F. Hoffmann-La Roche Ltd
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Merck KGaA
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Treatment Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Alnylam Pharmaceuticals, Inc.
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Treatment Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global amyloidosis treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5 Global amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 6 North America amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8 North America amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 9 U.S. amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 U.S. amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 11 Canada amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12 Canada amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 13 Mexico amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14 Mexico amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 15 Europe amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17 Europe amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 18 UK amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 UK amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 20 Germany amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 22 France amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 France amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 24 Italy amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 26 Spain amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 28 Norway amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Norway amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 30 Denmark amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31 Denmark amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 32 Sweden amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33 Sweden amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 37 Japan amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Japan amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 39 China amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40 China amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 41 India amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42 India amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 43 Australia amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Australia amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 45 South Korea amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46 South Korea amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 47 Thailand amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48 Thailand amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 49 Latin America amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Latin America amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 52 Brazil amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 54 Argentina amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55 Argentina amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 59 South Africa amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 South Africa amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 63 UAE amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64 UAE amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 Kuwait amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Amyloidosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and treatment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Amyloidosis treatment market dynamics
  • Fig. 12 Amyloidosis treatment market: Porter's five forces analysis
  • Fig. 13 Amyloidosis treatment market: PESTLE analysis
  • Fig. 14 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 15 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Immunosuppressive drugs market, 2021 - 2033 (USD Million)
  • Fig. 17 Transplantation market, 2021 - 2033 (USD Million)
  • Fig. 18 Supportive care market, 2021 - 2033 (USD Million)
  • Fig. 19 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 End use market, 2021 - 2033 (USD Million)
  • Fig. 22 Hospitals & clinics market, 2021 - 2033 (USD Million)
  • Fig. 23 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 24 Home care settings market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 Amyloidosis treatment market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 70 MEA amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework